White will be the first person living with CF to lead the Board into a new era of CF
Site Search
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Funding will support preclinical research and early-stage clinical trials
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023